SignalChem Lifesciences Corporation
3 clinical trials · Sponsor
◉ Watch SignalChem Lifesciences Corporation
| Record | Firm | Date |
|---|---|---|
| Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (NCT05860296) | SignalChem Lifesciences Corporation | 2023-05-31 |
| Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects (NCT05278845) | SignalChem Lifesciences Corporation | 2022-02-12 |
| Safety Study of SLC-391 in Subjects With Solid Tumors (NCT03990454) | SignalChem Lifesciences Corporation | 2019-09-17 |
Track SignalChem Lifesciences Corporation automatically
Every clearance here is in the API, with alerts when new ones post.